|
Characteristics
|
Cases (%)
|
Unmethylated (%)
|
Methylated (%)
|
p value
|
|---|
|
Age (years)
|
|
≤50
|
78 (56.93)
|
21 (26.92)
|
57 (73.08)
|
0.571
|
|
>50
|
59 (43.07)
|
19 (32.20)
|
40 (67.80)
| |
|
Age at menarche
|
|
≤12
|
26 (18.98)
|
8 (30.77)
|
18 (69.23)
|
0.815
|
|
>12
|
111 (81.02)
|
32 (28.83)
|
79 (71.17)
| |
|
Menopausal status
|
|
Premenopausal
|
40 (29.20)
|
12 (30)
|
28 (70)
|
1
|
|
Postmenopausal
|
97 (70.80)
|
28 (28.87)
|
69 (71.13)
| |
|
Age at menopause
|
|
≤45
|
33 (34.02)
|
12 (36.36)
|
21 (63.64)
|
0.249
|
|
>45
|
64 (65.98)
|
16 (25)
|
48 (75)
| |
|
ER status
|
|
Positive
|
81 (59.12)
|
27 (33.33)
|
54 (66.67)
|
0.252
|
|
Negative
|
56 (40.88)
|
13 (23.21)
|
43 (76.79)
| |
|
PR status
|
|
Positive
|
47 (34.31)
|
12 (25.53)
|
35 (74.47)
|
0.556
|
|
Negative
|
90 (65.69)
|
28 (31.11)
|
62 (68.89)
| |
|
Her2 status
|
|
Positive
|
66 (48.18)
|
18 (27.27)
|
48 (72.73)
|
0.708
|
|
Negative
|
71 (51.82)
|
22 (30.99)
|
49 (69.01)
| |
|
Molecular subtypes of breast cancer
|
|
Luminal A
|
46 (33.58)
|
16 (34.78)
|
30 (65.22)
|
0.584
|
|
Luminal B
|
38 (27.74)
|
12 (31.58)
|
26 (68.42)
| |
|
Her2-enriched
|
28 (20.44)
|
6 (21.43)
|
22 (78.57)
| |
|
TNBC
|
25 (18.25)
|
6 (24)
|
19 (76)
| |
|
Tumor size
|
|
≤5
|
55 (40.15)
|
15 (27.27)
|
40 (72.73)
|
0.707
|
|
>5
|
82 (59.85)
|
25 (30.49)
|
57 (69.51)
| |
|
Lymph node status
|
|
Positive
|
99 (72.26)
|
29 (29.29)
|
70 (70.71)
|
1
|
|
Negative
|
38 (27.74)
|
11 (28.95)
|
27 (71.05)
| |
|
Clinical stage
|
|
I+II
|
45(32.85)
|
11 (24.44)
|
34 (75.56)
|
0.43
|
|
III+IV
|
92(67.15)
|
29 (31.52)
|
63 (68.48)
| |
|
Histological grade
|
|
I+II
|
95 (69.34)
|
27 (28.42)
|
68 (71.58)
|
0.839
|
|
III
|
42 (30.66)
|
13 (30.95)
|
29 (69.05)
| |
- p value (Fisher’s Exact Test), Bonferroni significance level p ≤ 0.005
